Pirfenidone Sensitizes NCI-H460 Non-Small Cell Lung Cancer Cells to Paclitaxel and to a Combination of Paclitaxel with Carboplatin

Pirfenidone, an antifibrotic drug, has antitumor potential against different types of cancers. Our work explored whether pirfenidone sensitizes non-small cell lung cancer (NSCLC) cell lines to chemotherapeutic treatments. The cytotoxic effect of paclitaxel in combination with pirfenidone against thr...

Descripción completa

Detalles Bibliográficos
Autores principales: Branco, Helena, Oliveira, Júlio, Antunes, Catarina, Santos, Lúcio L., Vasconcelos, Maria Helena, Xavier, Cristina P. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8998757/
https://www.ncbi.nlm.nih.gov/pubmed/35408988
http://dx.doi.org/10.3390/ijms23073631

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8998757/
https://www.ncbi.nlm.nih.gov/pubmed/35408988
http://dx.doi.org/10.3390/ijms23073631

Ejemplares similares